Open AccessAsymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus
Author(s) -
Hiroyuki Konya,
Masayuki Miuchi,
Kahori Satani,
Shinji Matsutani,
Y Yano,
Taku Tsunoda,
Takashi Ikawa,
Toshihiro Matsuo,
Fumihiro Ochi,
Yoshiki Kusunoki,
Masaru Tokuda,
Tomoyuki Katsuno,
Tomoya Hamaguchi,
Junichiro Miyagawa,
Mitsuyoshi Namba
Publication year - 2015
Publication title -
world journal of experimental medicine
Language(s) - English
Resource type - Journals
ISSN - 2220-315X
DOI - 10.5493/wjem.v5.i2.110
Subject(s) - medicine , asymmetric dimethylarginine , type 2 diabetes mellitus , diabetes mellitus , cardiology , biomarker , fibrinogen , risk factor , myocardial infarction , endocrinology , arginine , biochemistry , chemistry , amino acid
Cardiovascular (CV) complications are an essential causal element of prospect in diabetes mellitus (DM), with carotid atherosclerosis being a common risk factor for prospective crisis of coronary artery diseases and/or cerebral infarction in DM subjects. From another point of view, asymmetric dimethylarginine (ADMA) has been established as an inhibitor of endogenous nitric oxide synthesis and the relationship between ADMA and arteriosclerosis has been reported. In our study with 87 type 2 DM (T2DM) patients, we have examined whether ADMA and other CV risk factors are the useful predictors of DMCV complications. After the measurement of the respective CV risk factors, we have followed the enrolled T2DM patients for 5 years. We have finally analyzed 77 patients. DMCV complications developed in 15 cases newly within 5 years, and 4 cases recurred. The concentrations of ADMA in plasma were markedly more elevated in 19 DM patients with CV complications than in 58 DM patients without CV complications. Urinary albumin (U-Alb), mean intimal-medial thickness (IMT) and ankle brachial index (ABI) were also higher in patients with CV complications. Multiple regression analyses showed that U-Alb had an influence on the high level of ADMA (standardized β = 6.59, P = 0.00014) independently of age, systolic BP, fibrinogen, mean IMT, plaque score, and ABI. The review indicates what is presently known regarding plasma ADMA that might be a new and meaningful biomarker of CV complications in DM subjects.